Dyadic International Reports FY 2025 Earnings Results

Written by Emily J. Thompson, Senior Investment Analyst

Source: seekingalpha

Updated: 1 hour ago

0mins

DYAI+3.32%

Should l Buy DYAI?

Source: seekingalpha

Earnings Performance: Dyadic International reported a FY 2025 GAAP EPS of -$0.23, aligning with market expectations, indicating ongoing challenges in profitability.
Revenue Decline: The company's revenue for FY 2025 was $3.09 million, representing an 11.7% year-over-year decrease and missing market expectations by $0.77 million, reflecting a lack of sales growth.
Cash Flow Status: As of December 31, 2025, Dyadic's total cash, cash equivalents, restricted cash, and investment-grade securities amounted to $8.6 million, down from $9.29 million in 2024, highlighting increased liquidity pressure.
Future Outlook: Dyadic aims to achieve product revenue growth and commercialization milestones in 2026 while expanding partnerships, intending to improve future financial performance and market competitiveness.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy DYAI?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on DYAI

About DYAI

Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica, which the Company named C1. The Compny’s lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

DYADIC INTERNATIONAL, INC. Reports FY EPS of USD -0.23

13 hours agomoomoo

Company Overview: DYA DIC International, Inc. is a company involved in various sectors, including finance and technology.
Market Performance: The company's stock, FYEP, is currently trading at $0.23, indicating its market position and investor interest.

Dyadic Launches AlbuFree™ DX Recombinant Human Albumin

12 hours agoNewsfilter

Product Commercialization Progress: Proliant Health & Biologicals successfully launched AlbuFree™ DX recombinant human albumin in February 2026, with Dyadic entitled to a share of profits from sales, marking a significant step in the company's commercialization efforts in the biopharmaceutical sector.
Strategic Collaboration Expansion: Dyadic expanded its partnership with Fermbox Bio, launching the first commercialized animal-origin-free DNase I (RNase-free), which not only enriches Dyadic's product portfolio but also enhances its competitiveness in the biotechnology market.
OEM Distribution Agreement Signed: Dyadic entered into an OEM distribution agreement with IBT Bioservices to commercialize recombinant DNase I and transferrin through IBT's global distribution channels, which is expected to significantly enhance Dyadic's market reach and sales capabilities.
Nutrition Market Development Agreement: Dyadic signed a development and commercialization agreement with BRIG Bio to produce animal-free bovine alpha-lactalbumin, which is anticipated to create new revenue streams for the global nutrition market, further driving the company's growth strategy.